Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis

Due to the increased incidence and recurrence of Clostridium difficile infection, health care providers are seeking new and alternative treatments to the standard antibiotic therapy. The objective of this article is to present a review on the background, microbiologic efficacy, clinical efficacy, and safety of fecal microbiota transplantation and to provide an overview of emerging treatment options currently under investigation. Emerging treatment options discussed include the use of monoclonal antibodies directed against toxins A and B, C difficile vaccination, and transplantation of nontoxigenic C difficile strains.

Download Full-text

Fecal Microbiota Transplantation is Highly Effective for Treatment of Clostridium Difficile Infection in Patiants with Inflammatory Bowel Disease; A Meta-Analysis

Gastroenterology ◽

10.1016/s0016-5085(17)33348-6 ◽

2017 ◽

Vol 152 (5) ◽

pp. S988

Author(s):

Amir Kashani ◽

David Q. Shih

Keyword(s):

Inflammatory Bowel Disease ◽

Clostridium Difficile ◽

Clostridium Difficile Infection ◽

Bowel Disease ◽

Fecal Microbiota Transplantation ◽

Meta Analysis ◽

Fecal Microbiota ◽

Highly Effective ◽

Inflammatory Bowel

Download Full-text

Antimicrobial therapy ofClostridium difficileinfection. Systematic literature review and meta-analysis

Orvosi Hetilap ◽

10.1556/oh.2013.29627 ◽

2013 ◽

Vol 154 (23) ◽

pp. 890-899 ◽

Cited By ~ 1

Author(s):

Valentin Brodszky ◽

László Gulácsi ◽

Endre Ludwig ◽

Gyula Prinz ◽

János Banai ◽

...

Keyword(s):

Systematic Review ◽

Clostridium Difficile ◽

Clostridium Difficile Infection ◽

Clinical Cure ◽

Meta Analysis ◽

Scientific Evidence ◽

Pharmaceutical Products ◽

Efficacy And Safety ◽

The Past ◽

Significant Difference

Introduction:Clostridium difficile is the leading cause of antibiotic associated infectious nosocomial diarrhoea. Limited number of new pharmaceutical products have been developed and registered in the past decades for the treatment of Clostridium difficile infection. The available scientific evidence is limited and hardly comparable. Aim: To analyse the clinical efficacy and safety of metronidazole, vancomycin and fidaxomicin in the therapy of Clostridium difficile infection. Methods: Systematic review and meta-analysis of the literature data. Results: Meta-analysis of literature data showed no significant difference between these antibiotics in clinical cure endpoint (odss ratios: fidaxomicin vs. vancomycin 1.19; vancomycin vs. metronidazol 1.69 and fidaxomicin vs. metronidazol 2.00). However, fidaxomicin therapy was significantly more effective than vancomicin and metronidazol in endpoints of recurrence and global cure (odds ratios: fidaxomicin vs. vancomycin 0.47; vancomycin vs. metronidazol 0.91 és fidaxomicin vs. metronidazol 0.43). There was no significant difference between fidaxomicin, vancomycin and metronidazole in safety endpoints. Conclusions: Each antibiotic similarly improved clinical cure. Fidaxomicin was the most effective therapeutic alternative in lowering the rate of recurrent Clostridium difficile infections. Orv. Hetil., 2013, 154, 890–899.

Download Full-text